Limits...
Dengue Vaccines: A Perspective from the Point of View of Intellectual Property.

da Veiga CP, da Veiga CR, Del Corso JM, da Silva WV - Int J Environ Res Public Health (2015)

Bottom Line: The results show that 93% of patents were granted since 2000, the majority belonging to the United States and Europe, although the share of patents from developing countries has increased.Finally, in this study, the main holders showed high knowledge absorption and generated capabilities.Therefore, this issue suggests that to overcome the difficulty of translational R & D it is necessary to stimulate the generation of knowledge and relevant scientific research, to enable the productive sector to have the capacity to absorb knowledge, to turn it into innovation, and to articulate partnerships and collaboration.

View Article: PubMed Central - PubMed

Affiliation: Pontifical Catholic University of Paraná, PUCPR, Rua Imaculada Conceição, 1155 Prado Velho, 80215-901 Curitiba, PR, Brazil. claudimar.veiga@gmail.com.

ABSTRACT
Dengue is a serious infectious disease and a growing public health problem in many tropical and sub-tropical countries. To control this neglected tropical disease (NTD), vaccines are likely to be the most cost-effective solution. This study analyzed dengue vaccines from both a historical and longitudinal perspective by using patent data, evaluating the geographic and time coverage of innovations, the primary patent holders, the network of cooperation and partnership for vaccine research and development (R & D), the flow of knowledge and the technological domain involved. This study can be seen as an example of the use of patent information to inform policy discussions, strategic research planning, and technology transfer. The results show that 93% of patents were granted since 2000, the majority belonging to the United States and Europe, although the share of patents from developing countries has increased. Unlike another NTDs, there is great participation of private companies in R & D of dengue vaccines and partnerships and collaboration between public and private companies. Finally, in this study, the main holders showed high knowledge absorption and generated capabilities. Therefore, this issue suggests that to overcome the difficulty of translational R & D it is necessary to stimulate the generation of knowledge and relevant scientific research, to enable the productive sector to have the capacity to absorb knowledge, to turn it into innovation, and to articulate partnerships and collaboration.

No MeSH data available.


Related in: MedlinePlus

Holders’ citations of main companies/institutions. Flow of knowledge of Sanofi Pasteur (Part A), US Department of Health and Human Service (Part B), US Army (Part C), US Government (Part D), Inviragen (Part E), Virogenetics (Part F), Center for Disease Control and Prevent (Part G), Takeda (Part H), Merck Sharp & Dohme (Part I), University Mahidol (Part J), Acambis (Part K), Bavarian Nordic (Part L).
© Copyright Policy
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4555291&req=5

ijerph-12-09454-f008: Holders’ citations of main companies/institutions. Flow of knowledge of Sanofi Pasteur (Part A), US Department of Health and Human Service (Part B), US Army (Part C), US Government (Part D), Inviragen (Part E), Virogenetics (Part F), Center for Disease Control and Prevent (Part G), Takeda (Part H), Merck Sharp & Dohme (Part I), University Mahidol (Part J), Acambis (Part K), Bavarian Nordic (Part L).

Mentions: The following analysis refers to Figure 8. In general, Figure 8 illustrates the great flow of knowledge among all analyzed holders. All private companies have citing/cited patents with US Government agencies (Part A, H, I, L). It is observed also an intense flow of knowledge among several US government agencies (Part B, C and D) and perhaps this is the superior performance reason reached for this country in the number of filed patents for dengue vaccines. Some holders such as Inviragen (Part E), CDC (Part G), Acambis (Part K) and Bavarian Nordic (Part L) display exclusively generator capabilities, while virogenetics (Part F) presents a totally opposite result, in other words, exclusive absorber capabilities.


Dengue Vaccines: A Perspective from the Point of View of Intellectual Property.

da Veiga CP, da Veiga CR, Del Corso JM, da Silva WV - Int J Environ Res Public Health (2015)

Holders’ citations of main companies/institutions. Flow of knowledge of Sanofi Pasteur (Part A), US Department of Health and Human Service (Part B), US Army (Part C), US Government (Part D), Inviragen (Part E), Virogenetics (Part F), Center for Disease Control and Prevent (Part G), Takeda (Part H), Merck Sharp & Dohme (Part I), University Mahidol (Part J), Acambis (Part K), Bavarian Nordic (Part L).
© Copyright Policy
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4555291&req=5

ijerph-12-09454-f008: Holders’ citations of main companies/institutions. Flow of knowledge of Sanofi Pasteur (Part A), US Department of Health and Human Service (Part B), US Army (Part C), US Government (Part D), Inviragen (Part E), Virogenetics (Part F), Center for Disease Control and Prevent (Part G), Takeda (Part H), Merck Sharp & Dohme (Part I), University Mahidol (Part J), Acambis (Part K), Bavarian Nordic (Part L).
Mentions: The following analysis refers to Figure 8. In general, Figure 8 illustrates the great flow of knowledge among all analyzed holders. All private companies have citing/cited patents with US Government agencies (Part A, H, I, L). It is observed also an intense flow of knowledge among several US government agencies (Part B, C and D) and perhaps this is the superior performance reason reached for this country in the number of filed patents for dengue vaccines. Some holders such as Inviragen (Part E), CDC (Part G), Acambis (Part K) and Bavarian Nordic (Part L) display exclusively generator capabilities, while virogenetics (Part F) presents a totally opposite result, in other words, exclusive absorber capabilities.

Bottom Line: The results show that 93% of patents were granted since 2000, the majority belonging to the United States and Europe, although the share of patents from developing countries has increased.Finally, in this study, the main holders showed high knowledge absorption and generated capabilities.Therefore, this issue suggests that to overcome the difficulty of translational R & D it is necessary to stimulate the generation of knowledge and relevant scientific research, to enable the productive sector to have the capacity to absorb knowledge, to turn it into innovation, and to articulate partnerships and collaboration.

View Article: PubMed Central - PubMed

Affiliation: Pontifical Catholic University of Paraná, PUCPR, Rua Imaculada Conceição, 1155 Prado Velho, 80215-901 Curitiba, PR, Brazil. claudimar.veiga@gmail.com.

ABSTRACT
Dengue is a serious infectious disease and a growing public health problem in many tropical and sub-tropical countries. To control this neglected tropical disease (NTD), vaccines are likely to be the most cost-effective solution. This study analyzed dengue vaccines from both a historical and longitudinal perspective by using patent data, evaluating the geographic and time coverage of innovations, the primary patent holders, the network of cooperation and partnership for vaccine research and development (R & D), the flow of knowledge and the technological domain involved. This study can be seen as an example of the use of patent information to inform policy discussions, strategic research planning, and technology transfer. The results show that 93% of patents were granted since 2000, the majority belonging to the United States and Europe, although the share of patents from developing countries has increased. Unlike another NTDs, there is great participation of private companies in R & D of dengue vaccines and partnerships and collaboration between public and private companies. Finally, in this study, the main holders showed high knowledge absorption and generated capabilities. Therefore, this issue suggests that to overcome the difficulty of translational R & D it is necessary to stimulate the generation of knowledge and relevant scientific research, to enable the productive sector to have the capacity to absorb knowledge, to turn it into innovation, and to articulate partnerships and collaboration.

No MeSH data available.


Related in: MedlinePlus